why choose us

First received: December 20, 2022

Clinical Trial: International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Study Status: Completed

Recruit Status: RECRUITING

Condition: Plasma Cell Myeloma

Study Type: INTERVENTIONAL


Official Title: International, Multi-center, Open-label, Treatment Extension Study in Patients With Multiple Myeloma Who Are Still Benefitting From Isatuximab-based Therapy Following Completion of a Phase 1, 2, or 3

Brief Summary: This is a multi-center, open-label, Phase 2 treatment extension study in patients with multiple myeloma who are still benefitting from isatuximab based therapy following completion of a Phase 1, 2, or 3 parental study.This Treatment Extension study has the purpose to provide continued access to isatuximab.Adult participants with multiple myeloma who have enrolled on an isatuximab parental study for which study objectives are completed will be eligible to be enrolled in this Treatment Extension study.The primary…

Read more